<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OALibJ</journal-id><journal-title-group><journal-title>Open Access Library Journal</journal-title></journal-title-group><issn pub-type="epub">2333-9705</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/oalib.1108219</article-id><article-id pub-id-type="publisher-id">OALibJ-116600</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject><subject> Business&amp;Economics</subject><subject> Chemistry&amp;Materials Science</subject><subject> Computer Science&amp;Communications</subject><subject> Earth&amp;Environmental Sciences</subject><subject> Engineering</subject><subject> Medicine&amp;Healthcare</subject><subject> Physics&amp;Mathematics</subject><subject> Social Sciences&amp;Humanities</subject></subj-group></article-categories><title-group><article-title>
 
 
  Human T-Cell Lymphotropic Virus (HTLV-1) Infection in the Democratic Republic of the Congo: A Review of a Forgotten Epidemic
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jean</surname><given-names>Yves D. Kabasele</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Idris</surname><given-names>M. Mwanaut</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Divine</surname><given-names>Chuga</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Médard</surname><given-names>O. Okonda</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Christian</surname><given-names>K. Thsibumbu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ludovic</surname><given-names>Ilombe</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Simplice</surname><given-names>K. Makoka</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cagod</surname><given-names>I. Basele</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Elvis</surname><given-names>T. Kateba</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ben</surname><given-names>I. Bulanda</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Berry</surname><given-names>I. Bongenya</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Erick</surname><given-names>N. Kamangu</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Faculty of Medicine, Technological University Bel Campus, Kinshasa, Democratic Republic of the Congo</addr-line></aff><aff id="aff3"><addr-line>Service of Molecular Biochemistry, Department of Basic Sciences, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo</addr-line></aff><aff id="aff1"><addr-line>“Focus HIV/AIDS” Research Group, Kinshasa, Democratic Republic of the Congo</addr-line></aff><pub-date pub-type="epub"><day>31</day><month>03</month><year>2022</year></pub-date><volume>09</volume><issue>04</issue><fpage>1</fpage><lpage>8</lpage><history><date date-type="received"><day>23,</day>	<month>November</month>	<year>2021</year></date><date date-type="rev-recd"><day>15,</day>	<month>April</month>	<year>2022</year>	</date><date date-type="accepted"><day>18,</day>	<month>April</month>	<year>2022</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background: The distribution of HTLV affects nearly 7 million people around the world. The prevalence of this infection varies among different geographic regions as well as populations. 
  Objective: The objective of this review was to present the epidemiological data on HTLV infection in the Democratic Republic of
   the Congo. 
  Method: This review consisted of cataloging various studies, published articles and summaries presented in scientific conferences having as a subject of interest the epidemiology of HTLV in the Democratic Republic of
   the Congo (DRC). The search was done using MEDLINE/PubMed, Embase (Via Ovid), Cochrane, Google scholar, and POPLINE. To identify the articles from the different sources, the search was carried out using the following keywords: “HTLV, HTLV Infection, HTLV Epidemiology, Kinshasa, Democratic Republic of
   the Congo”. Publications were selected according to the relevance of the methodology as well as the results and the representativeness of the samples. 
  Results: In 1990, Kayembe K. et al. conducted a study in the city of Lisala on 32 patients screened for chronic symmetrical spastic paraparesis of which 25 (96%) had anti-HTLV-1 markers in their serum. Goubau P. et al. had 102 sera samples collected in 1970 from a population of Bambuti pygmies in Zaire, 14 (13.7%) were positive for HTLV-2. Jeannel D. et al. conducted a study in Inongo in 1990 on 1162 patients, 36 (3.1%) were positive for anti-HTLV-1 markers. In the same year, Moulia-Pelat J.P. et al. conducted 2 studies, one on 230 Pygmies and the other on 680 Bantu, the prevalence of HTLV markers was 8.3% and 5.5% in Pygmies and Bantu respectively. In another study carried out by Goubau P. et al. in 1993, the prevalence of HTLV varied between 1% among pregnant women in Kinshasa and 15% among blood donors in Basankusu in Zaire. In 1995, Eric Delaporte et al. worked on 2349 different samples, 43 cases (3.7%) of pregnant women and 86 cases (7.3%) of prostitutes were diagnosed positive for HTLV. Between 1994 and 1998, 41 samples from women with spastic paralysis of the lower limbs were collected by Tshala KD et al., no sample was positive for HTLV. 
  Conclusion: This analysis shows that HTLV infection was of interest in the nineties and has lost interest today. Its prevalence in this decade was between 1% and 15% in the Democratic Republic of
   the Congo. It was higher than that of HIV during the same period.
 
</p></abstract><kwd-group><kwd>HTLV</kwd><kwd> Infection</kwd><kwd> Epidemiology</kwd><kwd> Democratic Republic of the Congo</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Human Lymphotropic T-cell virus type 1 and 2 (HTLV-1 and HTLV-2) belong to the family Retroviridae and the genus deltaretrovirus [<xref ref-type="bibr" rid="scirp.116600-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.116600-ref2">2</xref>]. HTLV-1 and HTLV-2 were the first pathogenic human retroviruses to be identified in humans in the 1980s [<xref ref-type="bibr" rid="scirp.116600-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.116600-ref2">2</xref>].</p><p>For a long time, the scientific world considered HTLV to be the probable cause of Acquired Immunodeficiency Syndrome (AIDS) [<xref ref-type="bibr" rid="scirp.116600-ref3">3</xref>].</p><p>The distribution of HTLV-1 affects nearly 7 million (5 - 10 million) people worldwide [<xref ref-type="bibr" rid="scirp.116600-ref4">4</xref>]. HTLV-1 is one of the most potent oncogenic human viruses [<xref ref-type="bibr" rid="scirp.116600-ref5">5</xref>].</p><p>Etiologically, HTLV-1 has been associated with adult T cell leukemia/lymphoma, which is a very aggressive and fatal malignant tumor. HTLV-1 is also associated with other inflammatory disorders, including infectious dermatitis and uveitis [<xref ref-type="bibr" rid="scirp.116600-ref6">6</xref>]. In addition, a recent study showed that HTLV-1 was associated with atherosclerosis in the elderly in an area of high seroprevalence [<xref ref-type="bibr" rid="scirp.116600-ref7">7</xref>].</p><p>HTLV-1/2 has a typical latency period of 20 to 30 years after infection. Hence, infected people can remain asymptomatic carriers for many years, while transmitting the virus [<xref ref-type="bibr" rid="scirp.116600-ref8">8</xref>].</p><p>The prevalence of this infection varies among different geographic regions as well as populations. HTLV-1 has extensive but uneven worldwide distribution. Highly endemic areas include sub-Saharan Africa, the Caribbean, parts of South America and southern Japan. HTLV-2 infection has an even more restricted distribution than that of HTLV, mainly among African Pygmies and Native Americans of North, Central and South America [<xref ref-type="bibr" rid="scirp.116600-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.116600-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.116600-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.116600-ref11">11</xref>]. It was believed that, from the early years, HTLV-2 was spread by Injection Drug Users (IDU), so in the United States and southern Europe, the prevalence rates were higher, ranging from 10% to 15% or more, have been described [<xref ref-type="bibr" rid="scirp.116600-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.116600-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.116600-ref14">14</xref>].</p><p>The routes of transmission of the human T-Lymphotropic virus include vertical transmission from infected mothers to newborns and through breastfeeding, unprotected sexual practice, parenteral transmission by transfusion, organ transplantation and needle distribution, contaminated syringes in intravenous drug addicts [<xref ref-type="bibr" rid="scirp.116600-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.116600-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.116600-ref16">16</xref>]. Evidence has shown that transfusion of HTLV infected blood is perhaps the most efficient mode of transmission of the virus due to the presence of lymphocytes infected, with a seroconversion rate of 27% to 63% after exposure to seropositive cellular blood components, but testing all blood donations in some high-income countries, transfusion-transmitted HTLV has been largely controlled [<xref ref-type="bibr" rid="scirp.116600-ref17">17</xref>].</p><p>Sub-Saharan Africa (SSA) is one of the most endemic regions for HTLV-1/2 [<xref ref-type="bibr" rid="scirp.116600-ref18">18</xref>]. Despite recommendations that blood intended for transfusion should be screened for transfusion-transmissible infections, screening for antibodies derived from blood from donated blood products has only been implemented in some countries, possibly due to limited resources.</p><p>Hence the objective of this analysis was to present the epidemiological data on HTLV infection in the Democratic Republic of the Congo.</p></sec><sec id="s2"><title>2. Methods</title><sec id="s2_1"><title>2.1. Literature Search</title><p>This study consisted in cataloging the various works, published articles and summaries presented in scientific conferences having as subject of interest the HTLV in Kinshasa and the Democratic Republic of the Congo (DRC). The publication was searched using MEDLINE/PubMed, Embase (Via Ovid), Cochrane, Google scholar, and POPLINE. To identify the articles from the different sources, the search was carried out using the keywords “HTLV, HTLV infection, HTLV epidemiology, Human Lymphotropic virus, Democratic Republic of the Congo”. The publications were selected according to the relevance of the methodology as well as the results and the representativeness of the samples.</p></sec><sec id="s2_2"><title>2.2. Study Selection</title><p>Studies were included if: 1) they estimated the prevalence of HTLV-1/2; and 2) were performed in DRC. Case studies, reviews, editorials and commentaries were excluded. Studies presented as abstracts or conference proceedings whose results did not contain sufficient information to properly assess the quality of the studies were excluded. <xref ref-type="table" rid="table1">Table 1</xref> presents the grading of the studies included in the revue.</p></sec></sec><sec id="s3"><title>3. Results and Discussion</title><p>The objective of this analysis was to present the various works carried out and published on the Human T-Cell Lymphotropic Virus in the Democratic Republic of the Congo (DRC). Seven studies were documented for the DRC, responding in particular to the various selection criteria. <xref ref-type="table" rid="table2">Table 2</xref> presents all the studies and data included in the revue. According to these various studies published and presented at conferences, the populations most targeted for studies on HTLV were Professional Sex Workers (PSW), pregnant women and pygmies.</p><p>In 1990, Kayembe K. et al. conducted a study in the city of Lisala in Equateur province in Zaire, currently the Democratic Republic of the Congo. Thirty-two (32) patients screened for chronic symmetrical spastic paraparesis were included for the search for HTLV-1 markers. Twenty-nine (29) presented with slowly progressing disease and 25 (96%), including 9 males and 16 females, had anti-HTLV-1 in their serum [<xref ref-type="bibr" rid="scirp.116600-ref19">19</xref>].</p><p>Goubau P. et al. had, out of 102 sera samples collected in 1970 from a population of Bambuti pygmies in Zaire, 14 positive samples for HTLV-2 [<xref ref-type="bibr" rid="scirp.116600-ref20">20</xref>]. This study has shown that HTLV was an ancient African virus already circulating in the community and not a new virus imported from the West.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Grading of the studies included in the review</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Study</th><th align="center" valign="middle" >Random sampling</th><th align="center" valign="middle" >Sample sizing</th><th align="center" valign="middle" >Study in DRC</th><th align="center" valign="middle" >HTLV</th><th align="center" valign="middle" >Subject description</th><th align="center" valign="middle" >Total</th></tr></thead><tr><td align="center" valign="middle" >Goubau P et al. [<xref ref-type="bibr" rid="scirp.116600-ref20">20</xref>]</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >4/5</td></tr><tr><td align="center" valign="middle" >Kayembe K. et al. [<xref ref-type="bibr" rid="scirp.116600-ref19">19</xref>]</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >4/5</td></tr><tr><td align="center" valign="middle" >Moulia-Pelat J.P. et al. [<xref ref-type="bibr" rid="scirp.116600-ref22">22</xref>]</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >5/5</td></tr><tr><td align="center" valign="middle" >Jeannel D. et al. [<xref ref-type="bibr" rid="scirp.116600-ref21">21</xref>]</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >5/5</td></tr><tr><td align="center" valign="middle" >Goubau P. et al. [<xref ref-type="bibr" rid="scirp.116600-ref23">23</xref>]</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >5/5</td></tr><tr><td align="center" valign="middle" >Delaporte E. et al. [<xref ref-type="bibr" rid="scirp.116600-ref24">24</xref>]</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >5/5</td></tr><tr><td align="center" valign="middle" >Tshala K.D. et al. [<xref ref-type="bibr" rid="scirp.116600-ref25">25</xref>]</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >√</td><td align="center" valign="middle" >4/5</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Presentation of data from included studies</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Study</th><th align="center" valign="middle" >Years</th><th align="center" valign="middle" >City</th><th align="center" valign="middle" >Number of patients included</th><th align="center" valign="middle" >Number of female patients</th><th align="center" valign="middle" >HTLV prevalence</th></tr></thead><tr><td align="center" valign="middle" >Goubau P. et al. [<xref ref-type="bibr" rid="scirp.116600-ref20">20</xref>]</td><td align="center" valign="middle" >1970</td><td align="center" valign="middle" >Bambuti, Za&#239;re</td><td align="center" valign="middle" >102</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >14 (14%)</td></tr><tr><td align="center" valign="middle" >Kayembe K. et al. [<xref ref-type="bibr" rid="scirp.116600-ref19">19</xref>]</td><td align="center" valign="middle" >1990</td><td align="center" valign="middle" >Lisala, Equateur, Za&#239;re</td><td align="center" valign="middle" >32˚</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >25 (96%)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Moulia-Pelat J.P. et al. [<xref ref-type="bibr" rid="scirp.116600-ref22">22</xref>]</td><td align="center" valign="middle"  rowspan="2"  >1990</td><td align="center" valign="middle"  rowspan="2"  >Kikaoula et Sangha, Za&#239;re</td><td align="center" valign="middle" >230 pygmies</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >8.3%</td></tr><tr><td align="center" valign="middle" >680 bantus</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >5.5%</td></tr><tr><td align="center" valign="middle" >Jeannel D. et al. [<xref ref-type="bibr" rid="scirp.116600-ref21">21</xref>]</td><td align="center" valign="middle" >1990</td><td align="center" valign="middle" >Inongo, Za&#239;re</td><td align="center" valign="middle" >1162</td><td align="center" valign="middle" >631</td><td align="center" valign="middle" >36 (3.1%)</td></tr><tr><td align="center" valign="middle" >Goubau P. et al. [<xref ref-type="bibr" rid="scirp.116600-ref23">23</xref>]</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4630</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >185 (4.0%)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Delaporte E. et al. [<xref ref-type="bibr" rid="scirp.116600-ref24">24</xref>]</td><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle"  rowspan="2"  >Za&#239;re</td><td align="center" valign="middle" >1183 PS</td><td align="center" valign="middle" >1183</td><td align="center" valign="middle" >86 (7.3%)</td></tr><tr><td align="center" valign="middle" >1166 &#216;</td><td align="center" valign="middle" >1166</td><td align="center" valign="middle" >42 (3.7%)</td></tr><tr><td align="center" valign="middle" >Tshala K.D. et al. [<xref ref-type="bibr" rid="scirp.116600-ref25">25</xref>]</td><td align="center" valign="middle" >1998</td><td align="center" valign="middle" >Pindi, Za&#239;re</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >0</td></tr></tbody></table></table-wrap><p>˚: Patients screened for chronic symmetrical spastic paraparesis; &#216;: Pregnant women.</p><p>Jeannel D. et al. conducted a study in Inongo, Bandundu province in Zaire in 1990. One thousand one hundred and sixty-two (1162) patients, including 631 women, were included in the study to look for markers of HTLV in this heterogeneous population. Thirty-six (36) patients, or 3.1%, were positive for anti-HTLV-1 markers, giving a rural prevalence of 3.1% for this infection [<xref ref-type="bibr" rid="scirp.116600-ref21">21</xref>].</p><p>The same year, Moulia-Pelat JP et al. conducted two consecutive studies, one on 230 pygmies and the other on 680 Bantu, for the search for markers of HTLV. The prevalence of HTLV markers was 8.3% and 5.5%, respectively, in Pygmies and Bantu. This study demonstrated that HTLV infection was more prevalent in this population than HIV infection, which was 0.9% and 5.4% respectively in Pygmies and Bantu; as well as, although immune to infections such as HIV (0.9%), pygmies are more affected by HTLV through vertical transmission [<xref ref-type="bibr" rid="scirp.116600-ref22">22</xref>].</p><p>According to the study carried by Goubau P. et al. in 1993, in 3 different countries with 4630 samples, there were more cases of HTLV-1 (168 cases, 3.6%) than HTLV-2 (2 cases, 0.04%) given that HTLV-1 is more diagnosed in drug addicts in the literature [<xref ref-type="bibr" rid="scirp.116600-ref23">23</xref>]. According to the different regions, the prevalence of HTLV varied between 1% among pregnant women in Kinshasa and 15% among blood donors in Basankusu for Zaire, mainly in the populations of pregnant women, blood donors and sex workers [<xref ref-type="bibr" rid="scirp.116600-ref23">23</xref>].</p><p>In 1995, Eric Delaporte et al. worked in the Bas-Congo and Bandundu regions, 2349 samples based on 1166 pregnant women and 1183 prostitutes. 43 cases (3.7%) of pregnant women and 86 cases (7.3%) of prostitutes were diagnosed positive for HTLV [<xref ref-type="bibr" rid="scirp.116600-ref24">24</xref>]. These data add to the literature when they talk about the different means of transmission of HTLV apart from maternal-fetal and sexual transmission [<xref ref-type="bibr" rid="scirp.116600-ref24">24</xref>].</p><p>Between 1994 and 1998, 41 samples from women with spastic paralysis of the lower limbs were collected by Tshala K.D. et al. as part of the Konzo Project study to determine the involvement of HTLV [<xref ref-type="bibr" rid="scirp.116600-ref25">25</xref>]. After analysis by ELISA and western blot, no sample was positive for HTLV [<xref ref-type="bibr" rid="scirp.116600-ref25">25</xref>].</p><p>Although often asymptomatic, HTLV infection presented as a public health problem for the DRC during the nineties. Its prevalence over the decade, according to the data collected in the different populations, varied between 1% and 15%. During the same period, infection with the Human Immunodeficiency Virus (HIV), which was also prevalent, and often confused with HTLV, had a prevalence that varied between 4.2% and 6.8% [<xref ref-type="bibr" rid="scirp.116600-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.116600-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.116600-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.116600-ref28">28</xref>].</p></sec><sec id="s4"><title>4. Conclusion</title><p>This analysis shows that the HTLV infection was indeed a reality in the Democratic Republic of the Congo as well as the HIV infection. It was interesting in the nineties. Its prevalence in this decade was between 1% and 15% in the Democratic Republic of the Congo while that of HIV was between 4.2% and 6.8% during the same period. However, since 1999, there have been no studies carried out on the carrying of HTLV. The epidemic has lost its value and been forgotten, but that does not mean that it no longer exists or it has been eradicated.</p></sec><sec id="s5"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="s6"><title>Cite this paper</title><p>Kabasele, J.Y.D., Mwanaut, I.M., Chuga, D., Okonda, M.O., Thsibumbu, C.K., Ilombe, L., Makoka, S.K., Basele, C.I., Kateba, E.T., Bulanda, B.I., Bongenya, B.I. and Kamangu, E.N. (2022) Human T-Cell Lymphotropic Virus (HTLV-1) Infection in the Democratic Republic of the Congo: A Review of a Forgotten Epidemic. Open Access Library Journal, 9: e8219. https://doi.org/10.4236/oalib.1108219</p></sec></body><back><ref-list><title>References</title><ref id="scirp.116600-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Gessain, A. and Cassar, O. (2012) Epidemiological Aspects and World Distibution of HTLV-1 Infection. Frontiers in Microbiology, 3, Article No. 388.</mixed-citation></ref><ref id="scirp.116600-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Tagaya, Y. and Gallo, R.C. (2017) The Exceptional Oncogenicity of HTLV-A. Frontiers in Microbiology, 8, Article No. 1425. https://doi.org/10.3389/fmicb.2017.01425</mixed-citation></ref><ref id="scirp.116600-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kengne, M., Tsata, D.C.W., Ndomgue, T. and Nwobegahay, J.M. (2018) Prevalence and Risk Factors of HTLV-1/2 and Other Blood Borne Infectious Diseases among Blood Donors in Yaounde Central Hospital, Cameroon. The Pan African Medical Journal, 30, Article No. 125. https://doi.org/10.11604/pamj.2018.30.125.14802</mixed-citation></ref><ref id="scirp.116600-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Gessain, A. and Mahieux, R. (2000) A Virus Called HTLV-1. Epidemiological Aspects. La Presse Médicale, 23, 2233-2239.</mixed-citation></ref><ref id="scirp.116600-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Proietti, F.A., Carneiro-Proietti, A.B., Catalan-Soares, B.C. and Murphy, E.L. (2005) Global Epidemiology of HTLV-I Infection and Associated Diseases. Oncogene, 24, 6058-6068. https://doi.org/10.1038/sj.onc.1208968</mixed-citation></ref><ref id="scirp.116600-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Yamanashi, H., Koyamatsu, J., Nagayoshi, M., Shimizu, Y., Kawashiri, S., Kondo, H., et al. (2018) Human T-Cell Leukemia Virus-1 Infection Is Associated with Atherosclerosis as Measured by Carotid Intima-Media Thickness in Japanese Community-Dwelling Older People. Clinical Infectious Diseases, 67, 291-294.  
https://doi.org/10.1093/cid/ciy168</mixed-citation></ref><ref id="scirp.116600-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Murphy, E.L., Wang, B., Sacher, R.A., Fridey, J., Smith, J.W., Nass, C.C., et al. (2004) Respiratory and Urinary Tract Infections, Arthritis, and Asthma Associated with HTLV-I and HTLV-II Infection. Emerging Infectious Diseases, 10, 109-116.  
https://doi.org/10.3201/eid1001.020714</mixed-citation></ref><ref id="scirp.116600-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Rocoux, D.F. and Murphy, E.L. (2004) The Epidemiology and Disease Outcomes of Human T-Lymphotropic Virus Type II. AIDS Reviews, 6, 144-154.</mixed-citation></ref><ref id="scirp.116600-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Kalyanaraman, V.S., Sarngadharan, M.G., Robert-Guroff, M., Miyoshi, I., Golde, D. and Gallo, R.C. (1982) A New Subtype of Human T-Cell Leukemia Virus (HTLV-II) Associated with a T-Cell Variant of Hairy Cell Leukemia. Science, 218, 571-573.  
https://doi.org/10.1126/science.6981847</mixed-citation></ref><ref id="scirp.116600-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Satake, M., Yamaguchi, K. and Tadokoro, K. (2012) Current Prevalence of HTLV-1 in Japan as Determined by Screening of Blood Donors. Journal of Medical Virology, 84, 327-335. https://doi.org/10.1002/jmv.23181</mixed-citation></ref><ref id="scirp.116600-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Cassar, O., Charavay, F., Bassot, S., Plancoulaine, S., Grangeon, J.-P. and Laumond-Barny, S. (2012) Divergent KSHV/HHV-8 Subtype D Stains in New Caledonia and Solomon Islands, Melanesia. Journal of Clinical Virology, 53, 214-218.  
https://doi.org/10.1016/j.jcv.2011.12.016</mixed-citation></ref><ref id="scirp.116600-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Biggar, R.J., Buskell-Bales, Z., Yakshe, P.N., Caussy, D., Gridley, G. and Seeff, L. (1991) Antibody to Human Retrovirus among Drug Users in Three East Coast American Cities, 1972-1976. The Journal of Infectious Diseases, 163, 57-63.  
https://doi.org/10.1093/infdis/163.1.57</mixed-citation></ref><ref id="scirp.116600-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Khabbaz, R.F., Onorato, I.M., Cannon, R.O., Hartley, T.M., Roberts, B., Hosein, B., et al. (1992) Seroprevalence of HTLV-1 and HTLV-2 among Intravenous Drug Users and Persons in Clinics for Sexually Transmitted Diseases. New England Journal of Medicine, 326, 375-380. https://doi.org/10.1056/NEJM199202063260604</mixed-citation></ref><ref id="scirp.116600-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Schreiber, G.B., Murphy, E.L., Horton, J.A., Wright, D.J., Garfein, R., Chien, H., et al. (1997) Risks Factors for Human T-Cell Lymphotropic Virus Types I and II (HTLV-I and -II) in Blood Donors: The Retrovirus Epidemiology Donor Study. NHLBI Retrovirus Epidemiology Donor Study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 14, 263-271.  
https://doi.org/10.1097/00042560-199703010-00011</mixed-citation></ref><ref id="scirp.116600-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Murphy, E.L., Figueroa, J.P., Gibbs, W.N., Brathwaite, A., Holding-Cobham, M., Waters, D., et al. (1989) Sexual Transmission of Human T-Lymphotropic Virus Type I (HTLV-I). Annals of Internal Medicine, 111, 555-560.  
https://doi.org/10.7326/0003-4819-111-7-555</mixed-citation></ref><ref id="scirp.116600-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Manns, A., Willks, R.J., Murphy, E.L., Haynes, G., Figueroa, J.P., Barnett, M., et al. (1992) A Prospective Study of Transmission by Transfusion of HTLV-I and Risk Factors Associated with Seroconversion. International Journal of Cancer, 51, 886-891.  
https://doi.org/10.1002/ijc.2910510609</mixed-citation></ref><ref id="scirp.116600-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Donegan, E., Lee, H., Operskalski, E.A., Shaw, G., Kleinman, S., Busch, M., et al. (1994) Transfusion Transmission of Retroviruses: Human T-Lymphotropic Virus Types I and II Compared with Human Immunodeficiency Virus Type 1. Transfusion, 34, 478-483. https://doi.org/10.1046/j.1537-2995.1994.34694295061.x</mixed-citation></ref><ref id="scirp.116600-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Vicento, B.D. and Kamangu, E.N. (2021) Human Leukemia Virus HTLV: An Overview. Open Access Library Journal, 8, Article ID: e7281.</mixed-citation></ref><ref id="scirp.116600-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kazadi, K., Goubau, P., Desmyter, J., Vlietinck, R. and Carton, H. (1990) A Cluster of HTLV-1 Associated Tropical Spastic Paraperesis in Equateur (Zaire): Ethnic and Familial Distribution. Journal of Neurology, Neurosurgery, and Psychiatry, 53, 4-10.  
https://doi.org/10.1136/jnnp.53.1.4</mixed-citation></ref><ref id="scirp.116600-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Goubau, P., Liu, H.F., De Lange, G.G., Vandamme, A.M. and Desmyter, J. (1993) HTLV-II seroprevalence in Pygmies across Africa since 1970. AIDS Research and Human Retroviruses, 9, 709-713. https://doi.org/10.1089/aid.1993.9.709</mixed-citation></ref><ref id="scirp.116600-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Jeannel, D., Garin, B., Kazadi, K., Singa, L. and De Thé, G. (1993) The Risk of Tropical Spastic Paraparesis Differs according to Ethnic Group among HTLV-1 Carriers in Inongo, Zaire. Journal of Acquired Immune Deficiency Syndromes, 6, 840-844.</mixed-citation></ref><ref id="scirp.116600-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Moulia-Pelat, J.P., Makuwa, M., Penchenier, L., Jannin, J., Fadat, G. and Miehakanda, J. (1992) Les Pygmées: Une ethnie à l’abri des MST? Médecine d’Afrique Noire, 39, 140-141.</mixed-citation></ref><ref id="scirp.116600-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Goubau, P., Desmyter, J., Swanson, P., Reynders, M., Shih, J., Surmont, I., Kazadi, K. and Lee, H. (1993) Detection of HTLV-1 and HTLV-2 Infection in Africans Using Type-Specific Envelope Peptides. Journal of Medical Virology, 39, 28-32.  
https://doi.org/10.1002/jmv.1890390107</mixed-citation></ref><ref id="scirp.116600-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Delaporte, E., Buve, A., Nzila, N., Goeman, J., Dazza, M.C., Henzel, D., Heyward, W., St-Louis, M., Piot, P. and Laga, M. (1995) HTLV-1 Infection among Prostitutes and Pregnant Women in Kinshasa, Zaire: How Important Is High-Risk Sexual Behavior? International Retrovirology Association, 8, 511-515.  
https://doi.org/10.1097/00042560-199504120-00012</mixed-citation></ref><ref id="scirp.116600-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Tshala, K.D., Nunga, M., Pukuta, S., Mutombo, L., Beya, E., Tshoko, K. and Mampunza, M. (1999) Coexistence de l’hysterie de masse, du konzo et du virus HTLV-1 en République Démocratique du Congo. Médecine Tropicale: Revue du corps de sante colonial, 59, 378-382.</mixed-citation></ref><ref id="scirp.116600-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Nelson, A.M., Hassig, S.E., Kayembe, M., Okonda, L., Mulanga, K., Brown, C., Kayembe, K., Kalengayi, M.M. and Mucclic, F.G. (1991) HIV-1 Seropositivity and Mortality at University Hospital, Kinshasa, Zaire, 1987. AIDS, 5, 583-586.  
https://doi.org/10.1097/00002030-199105000-00018</mixed-citation></ref><ref id="scirp.116600-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Ryder, R.W., Nsuami, M., Nsa, W., Kamenga, M., Badi, N., Utshudi, M. and Heyward, W.L. (1994) Mortality in HIV-1 Seropositive Women, Their Spouses and Their Newly Born Children during 36 Months of Follow-up in Kinshasa, Zaire. AIDS, 8, 667-672.  
https://doi.org/10.1097/00002030-199405000-00014</mixed-citation></ref><ref id="scirp.116600-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Mertens, T.E. and Low-Beer, D. (1996) VIH et SIDA: Ou va I’épidémie? Bulletin de l’Organisation mondiale de la Santé, 74, 243-252.</mixed-citation></ref></ref-list></back></article>